Key result
Initiation of ranolazine led to a marked reduction in premature ventricular complexes and control of ventricular tachycardia and symptoms in a patient with ischemic cardiomyopathy.
Why the study?
Does ranolazine reduce PVCs and VT in a patient with ischemic cardiomyopathy refractory to other antiarrhythmic drugs?
Case Report (n=1)
Does ranolazine reduce PVCs and VT in a patient with ischemic cardiomyopathy refractory to other antiarrhythmic drugs?
Ranolazine may be an effective treatment option for refractory PVCs and VT in patients with ischemic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for ranolazine in refractory VT; prospective trials needed before clinical adoption.
Nanda et al. (2010) conducted a case report in Ischemic cardiomyopathy, symptomatic PVCs, and monomorphic ventricular tachycardia (n=1). Ranolazine was evaluated on Reduction in PVCs and control of VT and symptoms. Initiation of ranolazine led to a marked reduction in premature ventricular complexes and control of ventricular tachycardia and symptoms in a patient with ischemic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: